Levels of C4d and C4d/C4 associate with clinical and histopathological treatment response in proliferative lupus nephritis. Complement activation markers, particularly C4d and the C4d/C4 ratio, are ...
A first-in-class oral inhibitor of the alternative complement pathway that drives the pathogenesis of primary glomerulonephritis, iptacopan (LNP023, Novartis), is showing early promise as the first ...
A 21-year-old white man presents with WHO type 4 diffuse proliferative glomerulonephritis (DPGN), hypertension, low serum C3, C4 complement and high serum level of anti-DNA antibodies, and spilling 6 ...
"Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market"Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) is a rare and progressive form of glomerular disease marked ...
Dublin, Dec. 12, 2024 (GLOBE NEWSWIRE) -- The "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): Market Insights, Epidemiology and Forecast to 2034" report has been added to ...
To clarify the association between certain immunologic factors and clinical activity in patients with systemic lupus erythematosus, 96 patients were studied. Those with antibodies to deoxyribonucleic ...
Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of Gazyva/Gazyvaro over standard therapy alone1,2Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a ...
Pharmaceutical Technology on MSN
EC approves Roche’s Gazyva to treat active lupus nephritis
Roche has received approval from the European Commission (EC) for its humanised monoclonal antibody Gazyva/Gazyvaro (obinutuzumab) along with mycophenolate mofetil (MMF), for adults with active Class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback